Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

By Eap Chin   Buclin Thierry   Hustert Elisabeth   Bleiber Gabriela   Golay Kerry   Aubert Anne-Catherine   Baumann Pierre   Telenti Amalio   Kerb Reinhold  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 4, 2004-06 ,pp. : 231-236

Springer Publishing Company

Access to resources Recommend Favorite

Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects

By Kim Kyoung-Ah  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 589-597

Springer Publishing Company

Access to resources Recommend Favorite

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects

By Xu Hong-Rong   Chen Wei-Li   Li Xue-Ning   Chu Nan-Nan  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 48, Iss. 8, 2010-08 ,pp. : 947-952

Informa Healthcare

Access to resources Recommend Favorite

Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam

By Drabant Sándor   Tóth Mária   Bereczki Andrea   Bajnógel Judit   Tömlö Judit   Klebovich Imre  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 587-588

Springer Publishing Company

Access to resources Recommend Favorite

Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers

By Krupka Emmanuel   Venisse Nicolas   Lafay Claire   Gendre David   Diquet Bertrand   Bouquet Serge   Perault Marie-Christine  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 8, 2006-08 ,pp. : 653-659

Springer Publishing Company

Access to resources Recommend Favorite